MAGEA4 and synovial sarcoma: The success in this phase 1 trial (NCT03132922) led to a phase 2 trial (SPEARHEAD-1, NCT04044768), with the ADP-A2M4 infused into 44 patients with SS and 8 patients with MRCL expressing MAGE-A4 and having the HLA-A2 haplotype [73].